Dehydroabietol | 1228-43-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: Dehydroabietol
• 英文别名: [(1R,4aS)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl]methanol
• CAS: 1228-43-9；3772-55-2；24035-43-6；102314-98-7
• 化学式: C₂₀H₃₀O
• 分子量: 286.458
• InChiKey: WSKGRAGZAQRSED-NRRUETGQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  Dehydroabietol 在 二环己烷并-18-冠醚-6 、 jones reagent 、 亚甲兰 、 sodium hydride 作用下， 以 二甲基亚砜 、 叔丁醇 为溶剂， 反应 5.0h， 生成
  参考文献：
  名称：

  Branching strategy in organic synthesis. 2. Reversal of olefin polarization with concomitant carbon-carbon bond formation

  摘要：

  DOI：

  10.1021/jo00336a051
• 作为产物：
  描述：

  dehydroabietic acid 在 硼烷 作用下， 以 四氢呋喃 为溶剂， 生成 Dehydroabietol
  参考文献：
  名称：

  Branching strategy in organic synthesis. 2. Reversal of olefin polarization with concomitant carbon-carbon bond formation

  摘要：

  DOI：

  10.1021/jo00336a051

文献信息

• General, Auxiliary-Enabled Photoinduced Pd-Catalyzed Remote Desaturation of Aliphatic Alcohols
  作者：Marvin Parasram、Padon Chuentragool、Yang Wang、Yi Shi、Vladimir Gevorgyan

  DOI：10.1021/jacs.7b08459

  日期：2017.10.25

  allows achieving superior degrees of regioselectivity and yields in the desaturation of alcohols compared to those obtained by the state-of-the-art desaturation methods. The HAT at unactivated C(sp3)-H sites is enabled by the easily installable/removable Si-auxiliaries. Formation of the key hybrid alkyl Pd-radical intermediates is efficiently induced by visible light from alkyl iodides and Pd(0) complexes

  已经开发了一种通用的、有效的和位点选择性的可见光诱导的 Pd 催化的脂肪醇远程去饱和成有价值的烯丙基、高烯丙基和双高烯丙基醇。这种转变通过混合 Pd 自由基机制进行，该机制协同结合了自由基方法的有利特征，例如简便的远程 CH HAT 步骤，与过渡金属催化化学（选择性β-氢消除步骤）的特征。与通过最先进的去饱和方法获得的那些相比，这允许在醇的去饱和中实现更高程度的区域选择性和收率。未激活的 C(sp3)-H 站点的 HAT 由易于安装/可拆卸的 Si 助剂启用。烷基碘化物和 Pd(0) 配合物的可见光可有效诱导关键杂化烷基 Pd-自由基中间体的形成。值得注意的是，该方法不需要外源性光敏剂或外部氧化剂。
• Novel abietane diterpenoid compound, and composition comprising extract of torreya nucifera, or abietane diterpenoid compounds or terpenoid compounds isolated from them for prevention and treatment of cardiovascular disease
  申请人：Jeong Tae-Sook

  公开号：US20070190192A1

  公开（公告）日：2007-08-16

  The present invention relates to a composition for the prevention and the treatment of cardiovascular disease containing extracts of T. nucifera or abietane diterpenoid compound or terpenoid compound isolated from the same as an effective ingredient. T. nucifera extracts or abietane diterpenoid compound or terpenoid compound isolated from the same of the present invention not only shows excellent anti-oxidative activity to LDL but also effectively inhibits ACAT activity. Further, T. nucifera extracts of the present invention reduce blood LDL cholesterol and total cholesterol. Therefore, the composition of the present invention can be effectively used for the prevention and the treatment of cardiovascular diseases including hyperlipidemia and atherosclerosis caused by the LDL oxidation and the synthesis and accumulation of cholesteryl ester.
• NOVEL ABIETANE DITERPENOID COMPOUND, AND COMPOSITION COMPRISING EXTRACT OF TORREYA NUCIFERA, OR ABIETANE DITERPENOID COMPOUNDS OR TERPENOID COMPOUNDS ISOLATED FROM THEM FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE
  申请人：Jeong Tae-Sook

  公开号：US20080299238A1

  公开（公告）日：2008-12-04

  The present invention relates to a composition for the prevention and the treatment of cardiovascular disease containing extracts of T. nucifera or abietane diterpenoid compound or terpenoid compound isolated from the same as an effective ingredient. T. nucifera extracts or abietane diterpenoid compound or terpenoid compound isolated from the same of the present invention not only shows excellent anti-oxidative activity to LDL but also effectively inhibits ACAT activity. Further, T. nucifera extracts of the present invention reduce blood LDL cholesterol and total cholesterol. Therefore, the composition of the present invention can be effectively used for the prevention and the treatment of cardiovascular diseases including hyperlipidemia and atherosclerosis caused by the LDL oxidation and the synthesis and accumulation of cholesteryl ester.
• PHARMACEUTICAL COMPOSITION AND TREATMENT METHOD FOR GENETIC DISEASE ASSOCIATED WITH SPLICING ABNORMALITIES
  申请人：KYOTO UNIVERSITY

  公开号：US20210205314A1

  公开（公告）日：2021-07-08

  A pharmaceutical composition for genetic diseases caused by an aberrant splicing regulation is provided. Provided are a pharmaceutical composition for preventing, ameliorating, suppressing progression of, and/or treating the genetic diseases caused by an aberrant splicing regulation, the pharmaceutical composition containing, as an active ingredient, a compound capable of suppressing an aberrant splicing regulation that contributes to the development or progression of genetic diseases caused by an aberrant splicing regulation, and a method for preventing, ameliorating, suppressing progression of, and/or treating the genetic diseases using a compound capable of suppressing an aberrant splicing regulation that contributes to the development or progression of genetic diseases caused by an aberrant splicing regulation.
• US7517542B2
  申请人：——

  公开号：US7517542B2

  公开（公告）日：2009-04-14